Mirae Asset Global Etfs Holdings Ltd. Lineage Cell Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 84,709 shares of LCTX stock, worth $45,742. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,709
Previous 81,061
4.5%
Holding current value
$45,742
Previous $73,000
42.47%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$22.5 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.66 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.91 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$3.22 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $91.7M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...